CNTB News and Press, Connect Biopharma Holdings Limited

SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases thr...

2024-06-12 18:00:14 ET More on Connect Biopharma Pfizer-Connect Biopharma deal for anti-inflammatory agent ends Seeking Alpha’s Quant Rating on Connect Biopharma Historical earnings data for Connect Biopharma Financial information for Connect Biopharma...

Rademikibart treatment significantly improved lung function at Week 12; improvements were observed as early as Week 1 and sustained through Week 24 Significant improvement in patient-reported asthma control occurred early and was sustained through Week 24 End of Phase 2 (EoP2) meeting i...

SAN DIEGO, CA and TAICANG, China, May 07, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic infl...

Dallas, Texas--(Newsfile Corp. - May 2, 2024) - Stonegate Healthcare Partners is providing an update on the publication of its report, titled "Transformative Therapies for Pruritus Management." This comprehensive report delves into the critical issue of pruritus, or chronic itch, and its impact o...

2024-04-17 13:27:11 ET Connect Biopharma ( NASDAQ: CNTB ) has decided to end a licensing deal with Pfizer ( NYSE: PFE ) for an oral anti-inflammatory agent named CBP-174 as part of its efforts to prioritize its lead asset, rademikibart.... Read the full article on Seek...

2024-04-16 16:31:50 ET More on Connect Biopharma Seeking Alpha’s Quant Rating on Connect Biopharma Historical earnings data for Connect Biopharma Financial information for Connect Biopharma Read the full article on Seeking Alpha For further det...

Reported two positive readouts for rademikibart, the Company’s lead asset, from the Global Phase 2b trial in moderate-to-severe persistent asthma and from the China pivotal trial in moderate-to-severe atopic dermatitis (AD) Type C meeting in AD and End-of-Phase 2 (EoP2) meeting in asth...

Organigram Holdings Inc. (OGI) is expected to report $-0.06 for Q2 2024 COMSovereign Holding Corp. (COMS) is expected to report for quarter end 2023-12-31 PriceSmart Inc. (PSMT) is expected to report for Q2 2024 Tilray Brands Inc. (TLRY) is expected to report $-0.04 for Q3 2024 Ux...

Connect Biopharma Holdings Limited (CNTB) is expected to report for Q4 2023